Using a wearable medical cuff device can facilitate the continuous monitoring of vital signs, physical activity, and complications in patients on intensive treatment regimens for aggressive haematologic malignancies, according to a recent study.
Combined data from the Singapore Armed Forces (SAF) and the Meteorological Service Singapore (MSS) show that a dew-point temperature ≥25.1°C on the same day (D) often leads to an increased risk of exertional heat injury (EHI) on the following day (D+1) during military training, reports a study.
In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.
New drug applications approved by US FDA as of 01-15 January 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The vasodilator ifenprodil together with sorafenib has been identified as a new drug combination for hepatocellular carcinoma (HCC) treatment by researchers from the University of Hong Kong (HKU) using clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) screen.